C83.35 Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb

Name of the Condition

• Diffuse Large B-Cell Lymphoma, Lymph Nodes of Inguinal Region and Lower Limb (ICD-10 Code: C83.35)

Summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma that originates in B-cells, a type of white blood cell. It is characterized by rapidly growing tumors in the lymph nodes or other lymphoid tissues. This code specifies involvement of the lymph nodes in the inguinal region and lower limb. DLBCL is one of the most common subtypes of non-Hodgkin lymphoma and can occur in various parts of the body.

Causes

The exact cause of DLBCL is not fully understood. It is believed to result from genetic mutations in B-cells, which may be triggered by factors such as previous infections (e.g., Epstein-Barr virus), immune system dysfunctions, or exposure to certain environmental agents. These mutations disrupt normal cell growth and division, leading to uncontrolled proliferation.

Risk Factors

• Advanced age (most common in older adults)
• Weakened immune system (e.g., from HIV, organ transplants, or immunosuppressive drugs)
• Family history of lymphoma
• Exposure to certain chemicals or radiation
• Chronic infections (e.g., hepatitis C)

Symptoms

• Swollen, painless lymph nodes in the inguinal region or lower limb
• Unexplained weight loss
• Fever
• Night sweats
• Fatigue
• Loss of appetite
• Pain or swelling in the affected limb

Diagnosis

Diagnosis involves a combination of physical examination, imaging studies (e.g., CT or PET scans), and biopsy of the affected lymph node. Laboratory tests, including blood work and flow cytometry, may also be performed to confirm the diagnosis and assess disease extent. Staging helps determine the spread of the lymphoma.

Treatment Options

Treatment typically includes chemoimmunotherapy (e.g., R-CHOP regimen) as the standard first-line approach. Radiation therapy may be used for localized disease or as an adjunct. For relapsed or refractory cases, additional therapies such as targeted agents or stem cell transplantation may be considered. Treatment plans are individualized based on patient factors and disease characteristics.

Prognosis and Follow-Up

Prognosis varies depending on factors like age, overall health, and disease stage at diagnosis. Many patients achieve remission with standard treatment, but some may experience recurrence. Regular follow-up with imaging and clinical assessments is essential to monitor for relapse or progression. Long-term surveillance is recommended to detect late effects or secondary malignancies.

Complications

Potential complications include treatment-related side effects (e.g., infection risk, organ toxicity), disease progression, or transformation to a more aggressive subtype. DLBCL can also spread to other organs (e.g., bone marrow, central nervous system) if left untreated or unresponsive to therapy.

Lifestyle & Prevention

While no specific prevention exists, maintaining a healthy immune system through balanced nutrition, regular exercise, and avoiding known risk factors (e.g., excessive radiation exposure) may support overall health. Prompt treatment of infections and managing immune-compromising conditions can reduce risk. Smoking cessation and limiting alcohol intake are also advisable.

When to Seek Professional Help

Seek medical attention if you experience persistent swollen lymph nodes, unexplained weight loss, fever, or other systemic symptoms. Early evaluation is critical for timely diagnosis and treatment. Consult a healthcare provider if symptoms worsen or new concerning signs (e.g., severe pain, neurological changes) develop.

Tips for Medical Coders

Use code C83.35 for diffuse large B-cell lymphoma specifically involving the lymph nodes of the inguinal region and lower limb. Ensure documentation clearly specifies the anatomical site to justify code assignment. Verify that the diagnosis aligns with histopathological confirmation of DLBCL and exclude other lymphoma subtypes or non-lymphoid malignancies.